Whether Fulgent is a value or a value trap depends on the short-term prospects for COVID-19 and the long-term prospects for its core sequencing business.
While large-cap stocks are usually safer, small-cap stocks are often way more exciting. If you own the right small cap, you can make a lot of money as your company becomes the large cap of tomorrow. This panel of Fool.com contributors has three small-cap COVID-19 stock ideas for intrepid investors.
Like many companies, Fulgent Genetics (NASDAQ: FLGT) has been labeled a "pandemic stock" by some investors. In the most recent quarter, 82% of Fulgent's revenue came from COVID-19 tests. In the most recent quarter, Fulgent's revenue grew to $126 million, a 124% increase over the third quarter of 2020.